137 related articles for article (PubMed ID: 12720571)
21. Prostate cancer incidence and survival in relation to education (United States).
Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
[TBL] [Abstract][Full Text] [Related]
22. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates.
Merrill RM; Feuer EJ; Warren JL; Schussler N; Stephenson RA
Am J Epidemiol; 1999 Oct; 150(8):848-60. PubMed ID: 10522656
[TBL] [Abstract][Full Text] [Related]
23. Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study.
Møller MH; Kristiansen IS; Beisland C; Rørvik J; Støvring H
BJU Int; 2016 Oct; 118(4):547-55. PubMed ID: 26497872
[TBL] [Abstract][Full Text] [Related]
24. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
Merrill RM
Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
[TBL] [Abstract][Full Text] [Related]
25. Cerebrovascular disease in Utah, 1968--1971.
Lyon JL; Bishop CT; Nielsen NS
Stroke; 1981; 12(5):564-6. PubMed ID: 7303040
[TBL] [Abstract][Full Text] [Related]
26. Gender differences in the association between religious involvement and depression: the Cache County (Utah) study.
Norton MC; Skoog I; Franklin LM; Corcoran C; Tschanz JT; Zandi PP; Breitner JC; Welsh-Bohmer KA; Steffens DC;
J Gerontol B Psychol Sci Soc Sci; 2006 May; 61(3):P129-36. PubMed ID: 16670181
[TBL] [Abstract][Full Text] [Related]
27. Spatial analysis of drug poisoning deaths in the American West, particularly Utah.
Kerry R; Goovaerts P; Vowles M; Ingram B
Int J Drug Policy; 2016 Jul; 33():44-55. PubMed ID: 27286759
[TBL] [Abstract][Full Text] [Related]
28. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
29. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
30. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
31. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
Gilliland F; Becker TM; Smith A; Key CR; Samet JM
Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
[TBL] [Abstract][Full Text] [Related]
32. Mass screening for prostate cancer in Korea: a population based study.
Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
[TBL] [Abstract][Full Text] [Related]
33. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
34. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
Mullan RJ; Jacobsen SJ; Bergstralh EJ; Slezak JM; Tindall DJ; Lieber MM; Roberts RO
BJU Int; 2005 May; 95(7):951-5. PubMed ID: 15839911
[TBL] [Abstract][Full Text] [Related]
35. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
[TBL] [Abstract][Full Text] [Related]
36. Quebec prostate cancer mortality dropped in 1996.
Meyer F; Moore L; Bairati I; Fradet Y
Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal screening for prostate cancer with prostate-specific antigen.
Smith DS; Catalona WJ; Herschman JD
JAMA; 1996 Oct 23-30; 276(16):1309-15. PubMed ID: 8861989
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk.
Hemminki K; Rawal R; Bermejo JL
Int J Cancer; 2005 Jan; 113(2):312-5. PubMed ID: 15386407
[TBL] [Abstract][Full Text] [Related]
40. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
